Betz C, Hall MN (2013) Where is mTOR and what is it doing there? J Cell Biol 203(4):563–574
Article
CAS
PubMed
PubMed Central
Google Scholar
Caccamo A, DePinto V, Messina A, Branca C, Oddo S (2014) Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer’s disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. J Neurosci 34:7988–7998
Article
CAS
PubMed
PubMed Central
Google Scholar
Cuervo AM, Bergamini E, Brunk E, Droge W, Ffrench M, Terman A (2005) Autophagy and aging: the importance of maintaining “clean” cells. Autophagy 1:131–140
Article
PubMed
Google Scholar
Diaz-Troya S, Perez-Perez ME, Florencio FJ, Crespo JL (2008) The role of TOR in autophagy regulation from yeast to plants and mammals. Autophagy 4:851–865
Article
CAS
PubMed
Google Scholar
Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates, 2nd edn. Academic Press, San Diego, CA
Google Scholar
Höllerhage M, Deck R, De Andrade A, Respondek G, Xu H, Rösler T, Salama M, Carlsson T, Yamada ES, Gad El Hak S, Goedert M, Oertel W, Höglinger GU (2015) Piericidin A aggravates tau pathology in P301S transgenic mice. PLoS One 9(12):e113557
Article
CAS
Google Scholar
Jiang T, JT Y, Zhu XC, Zhang QQ, Cao L, Wang HF (2014) Temsirolimus attenuates tauopathy in vitro and in vivo by targeting hyperphosphorylation and autophagic clearance. Neuropharmacology 85:121–130
Article
CAS
PubMed
Google Scholar
Klionsky DJ, Emr SD (2000) Autophagy as a regulated pathway of cellular degradation. Science 290:1717–1721
Article
CAS
PubMed
PubMed Central
Google Scholar
Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149:274–293
Article
CAS
PubMed
PubMed Central
Google Scholar
Li X, Alafuzoff I, Soininen H, Winblad B, Pei JJ (2005) Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer’s disease brain. FEBS J 272:4211–4220
Article
CAS
PubMed
Google Scholar
Ludolph AC, Kassubek J, Landwehrmeyer BG, Mandelkow E, Mandelkow EM, Burn DJ, Caparros-Lefebvre D, Frey KA, de Yebenes JG, Gasser T, Heutink P, Höglinger G, Jamrozik Z, Jellinger KA, Kazantsev A, Kretzschmar H, Lang AE, Litvan I, Lucas JJ, MG PL, Melquist S, Oertel W, Otto M, Paviour D, Reum T, Saint-Raymond A, Steele JC, Tolnay M, Tumani H, van Swieten JC, Vanier MT, Vonsattel JP, Wagner S, Wszolek ZK, Reisensburg Working Group for Tauopathies With Parkinsonism (2009) Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol 16(3):297–309
Article
CAS
PubMed
PubMed Central
Google Scholar
Nicks J, Lee S, Harris A, Falk DJ, Todd AG, Arredondo K, DunnWAJr NL (2014) Rapamycin improves peripheral nerve myelination while it fails to benefit neuromuscular performance in neuropathic mice. Neurobiol Dis 70:224–236
Article
CAS
PubMed
PubMed Central
Google Scholar
Ozcelik S, Fraser G, Castets P, Schaeffer V, Skachokova Z, Breu K, Clavaguera F, Sinnreich M, Kappos L, Goedert M, Tolnay M, Winkler DT (2013) Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS One 8(5):e62459
Article
CAS
PubMed
PubMed Central
Google Scholar
Rottscholl R, Haegele M, Jainsch B, Xu H, Respondek G, Hollerhage M, Rosler TW, Bony E, Le Ven J, Guerineau V, Schmitz-Afonso I, Champy P, Oertel WH, Yamada ES, Hoglinger GU (2016) Chronic consumption of Annonamuricata juice triggers and aggravates cerebral tau phosphorylation in wild-type and MAPT transgenic mice. J Neurochem 139(4):624–639
Article
CAS
PubMed
Google Scholar
Salama M, El-Hussiny M, Magdy A, Omran A, Alsayed A, Ashry A, Mohamed W (2017) Dual mTORC1/mTORC2 blocker as a possible therapy for tauopathy in cellular model. Metab Brain Dis 33(2):583–587
Article
CAS
PubMed
Google Scholar
SantaCruz K (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476–481
Article
CAS
PubMed
PubMed Central
Google Scholar
Siman R, Cocca R, Dong Y (2015) The mTOR inhibitor rapamycin mitigates perforant pathway neurodegeneration and synapse loss in a mouse model of early-stage Alzheimer-type tauopathy. PLoS One 10(11):e0142340
Article
CAS
PubMed
PubMed Central
Google Scholar
Sousa-Victor P, García-Prat L, Muñoz-Cánoves P (2015) Dual mTORC1/ C2 inhibitors: gerosuppressors with potential anti-aging effect. Oncotarget 6(27):23052–23054
Article
PubMed
PubMed Central
Google Scholar
Spillantini MG, Goedert M (2013) Tau pathology, and neurodegeneration. Lancet Neurol 12:609–622
Article
CAS
PubMed
Google Scholar
Tang Z, Bereczki E, Zhang H, Wang S, Li C, Ji X, Branca RM, Lehtiö J, Guan Z, Filipcik P, Xu S, Winblad B, Pei JJ (2013) Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease. J Biol Chem 288(22):15556–15570
Article
CAS
PubMed
PubMed Central
Google Scholar
Xu H, Rosler TW, Carlsson T, de Andrade A, Fiala O, Hollerhage M, Oertel WH, Goedert M, Aigner A, Hoglinger GU (2014) Tau silencing by siRNA in the P301S mouse model of tauopathy. Curr Gene Ther 14(5):343–351
Article
CAS
PubMed
Google Scholar
Yamada ES, Respondek G, Müssner S, de Andrade A, Höllerhage M, Depienne C, Rastetter A, Tarze A, Friguet B, Salama M, Champy P, Oertel WH, Höglinger GU (2014) Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phophorylation of tau in the brain of FTDP-17 transgenic mice. Exp Neurol 253C:113–125
Article
CAS
Google Scholar
Zhang X, Li L, Chen S, Yang D, WangY ZX, Wang Z, Le W (2011) Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy 7(4):412–425
Article
CAS
PubMed
Google Scholar